Table 4 Bivariate analysis of prognostic factors for incidence of pathological fractures

Gender

0.797

0.503–1.262

0.333

0.727

0.369–1.434

0.358

0.862

0.461–1.612

0.642

KPS

0.843

0.535–1.327

0.461

0.753

0.387–1.465

0.403

0.930

0.500–1.731

0.819

NSCLC

0.604

0.376–0.969

0.036

0.566

0.285–1.126

0.105

0.645

0.336–1.237

0.186

Breast cancer

0.562

0.284–1.113

0.098

0.745

0.318–1.746

0.498

0.369

0.111–1.225

0.103

Kidney cancer

1.071

0.595–1.928

0.818

2.008

0.928–4.345

0.076

0.534

0.204–1.398

0.202

Localization

0.970

0.607–1.548

0.897

0.618

0.292–1.308

0.208

1.351

0.725–2.517

0.343

Chemotherapy

1.020

0.647–1.609

0.931

1.295

0.657–2.555

0.455

1.329

0.704–2.511

0.381

Stability before RT

0.937

0.595–1.474

0.777

0.647

0.298–1.406

0.271

1.155

0.586–2.276

0.677

Stability after 3 months

0.993

0.594–1.660

0.980

0.776

0.363–1.660

0.514

1.266

0.505–3.174

0.614

Stability after 6 months

0.939

0.537–1.642

0.826

0.587

0.256–1.343

0.207

1.682

0.493–5.740

0.406

Bisphosphonates

0.939

0.573–1.538

0.803

0.606

0.288–1.274

0.186

1.313

0.676–2.550

0.421

Number of metastases

1.314

0.826–2.090

0.249

1.689

0.829–3.442

0.149

0.683

0.365–1.277

0.232